Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease

Circulation

Volumn 102, Issue 8, 2000, Pages 846-851

  Vita, Joseph A ^a,j   Yeung, Alan C ^b   Winniford, Michael ^c   Hodgson, John M ^d   Treasure, Charles B ^e   Klein, J Larry ^e   Werns, Steven ^f   Kern, Morton ^g   Plotkin, Diane ^h   Shih, W Joseph ^h   Mitchel, Yale ^h   Ganz, Peter ⁱ  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^g SAINT LOUIS UNIVERSITY HOSPITAL   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j BOSTON MEDICAL CENTER   (United States)

more..

Author keywords

Coronary disease; Endothelium; Lipids

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ASCORBIC ACID; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SIMVASTATIN; SUBSTANCE P;

ADULT; ARTERY DIAMETER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; INTRACORONARY INFUSION; MAJOR CLINICAL STUDY; MICROVASCULATURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 0034702906     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.8.846     Document Type: Article

References (20)

1. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries
2. Modulation of coronary vasomotor tone in humans: Progressive endothelial dysfunction with different early stages of coronary atherosclerosis
3. Cholesterol reduction in cardiovascular disease: Clinical benefits and possible mechanisms
4. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction
5. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
6. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group
8. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients
9. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia
10. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
11. The effect of cholesterol lowering and antioxidant therapy on endothelium-dependent coronary vasomotion
12. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelium function within 1 month
13. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) Trial
14. Coronary nitric oxide activity in hypertension and hypercholesterolemia: Comparison of acetylcholine and substance P
15. Impaired endothelium-dependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension: Different responses to acetylcholine and substance P
16. Nitric oxide activity in the human coronary circulation: Impact of risk factors for atherosclerosis
17. Validation of a Doppler guide wire for intravascular measurement of coronary artery flow velocity
18. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease
19. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease: A potential noninvasive marker of healing coronary endothelium
20. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart